Last reviewed · How we verify

Period 1 THYROGEN®, Period 2 GX-30

Genexine, Inc. · Phase 1 active Small molecule

Period 1 THYROGEN®, Period 2 GX-30 is a Small molecule drug developed by Genexine, Inc.. It is currently in Phase 1 development. Also known as: Thyrotropin alpha.

At a glance

Generic namePeriod 1 THYROGEN®, Period 2 GX-30
Also known asThyrotropin alpha
SponsorGenexine, Inc.
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Period 1 THYROGEN®, Period 2 GX-30

What is Period 1 THYROGEN®, Period 2 GX-30?

Period 1 THYROGEN®, Period 2 GX-30 is a Small molecule drug developed by Genexine, Inc..

Who makes Period 1 THYROGEN®, Period 2 GX-30?

Period 1 THYROGEN®, Period 2 GX-30 is developed by Genexine, Inc. (see full Genexine, Inc. pipeline at /company/genexine-inc).

Is Period 1 THYROGEN®, Period 2 GX-30 also known as anything else?

Period 1 THYROGEN®, Period 2 GX-30 is also known as Thyrotropin alpha.

What development phase is Period 1 THYROGEN®, Period 2 GX-30 in?

Period 1 THYROGEN®, Period 2 GX-30 is in Phase 1.

Related